Analyse
Fundierte Analysen zu Pharmamärkten, Lieferketten, Technologie und Regulierung
Analyse
6. Sept. 2026•1 Min. Lesezeit
Eli Lilly and Novo Nordisk vie for obesity drug market amid pricing and prescriber preferences
Surveys highlight price burden, prescriber preference and patient perception as key factors as Lilly and Novo Nordisk compete with oral GLP‑1 therapies.
Analyse
6. Sept. 2026•1 Min. Lesezeit
Pharmacies with '365' in name rise, indicating growing 365‑day service model
The share of pharmacies whose names include '365' has risen from 1.2% in 2021 to 2.79% in 2023, reflecting an expanding trend of year‑round operations.
Analyse
6. Sept. 2026•1 Min. Lesezeit
Hanmi Pharmaceutical signs $2.3B exclusive license with Genentech for obesity drug candidate HM17321
Hanmi Pharma secured an exclusive license with Genentech worth up to $2.3 billion for obesity/metabolic disease candidate HM17321, following a $1.26 billion deal earlier this year.
Analyse
6. Sept. 2026•1 Min. Lesezeit
Pharmacy franchise fees in Seoul deviate from traditional sales‑multiple formula
A 20‑pyeong pharmacy with 21 M KRW monthly sales was priced at 750 M KRW, while a 30 M KRW sales pharmacy fetched 600 M KRW, showing a shift from the usual 25‑30× sales rule.
Analyse
5. Sept. 2026•1 Min. Lesezeit
Jeil Pharm focuses Zaqubo production as Quzetas and Oncap halted, raising supply concerns
Domestic P‑CAB drug Zaqubo climbs to second market share, while Jeil Pharm stops production of twin Jastafrazan products Quzetas and Oncap, leaving their future supply uncertain.
Analyse
5. Sept. 2026•1 Min. Lesezeit
PharmaResearch’s Rejuran Cosmetic to Enter Singapore Sephora via Olive Young K‑Beauty Edit
PharmaResearch’s premium dermo‑cosmetic brand Rejuran Cosmetic will debut in Singapore Sephora’s online and offline stores from Sept 2 as part of Olive Young’s K‑Beauty Edit, accelerating its Southeast Asian expansion.
Analyse
5. Sept. 2026•1 Min. Lesezeit
EasyMedicom partners with ISM Korea to launch CHSCA and CHSCM certifications in Korea
EasyMedicom and ISM Korea are introducing ISCEA‑certified CHSCA and CHSCM healthcare supply‑chain qualifications in South Korea to develop local expertise.
Analyse
4. Sept. 2026•1 Min. Lesezeit
Jongkundang Q2 Outlook Steady on Obesity Drug Wegobi; Profit Forecast Slightly Below Consensus
Analyst Huh Hyemin of Kiwoom Securities forecasts Jongkundang's Q2 sales at 4.629 trillion KRW, up 8% YoY, but operating profit at 193 billion KRW, 13% lower, slightly below consensus.
Analyse
4. Sept. 2026•1 Min. Lesezeit
Dongguk Pharmaceutical projects Q2 sales rise on overseas cosmetics growth
Analyst Park Jong‑dae of Hana Securities forecasts Dongguk Pharmaceutical’s Q2 sales at 260.5 billion KRW and operating profit at 26.4 billion KRW, driven by strong U.S. Amazon cosmetics sales and expanding pharmacy‑cosmetics market.
Analyse
4. Sept. 2026•1 Min. Lesezeit
Pharma Companies Reshape Distribution Networks Amid Price‑Cut Policies
Government drug‑price cuts are pressuring pharma cost‑savings, prompting firms to shift to regional wholesale and accelerate independent sales operations, challenging traditional distributors.
Analyse
4. Sept. 2026•1 Min. Lesezeit
Kwangdong Pharma's V‑Line Corn Silk Tea Hits 1.6 Billion Cumulative Sales on 20th Anniversary
Kwangdong Pharmaceutical celebrates the 20th anniversary of its flagship ready‑to‑drink corn silk tea, announcing cumulative sales of 1.61258 billion bottles and unveiling new packaging.
Analyse
4. Sept. 2026•1 Min. Lesezeit
BooKwang Pharma's Regadex ranks second in South Korea's liver disease combo market within a year
Regadex, a liver disease combination drug by BooKwang Pharma, achieved the second highest prescription volume in South Korea's liver disease combo market within a year of launch.